BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval
Executive Summary
The LAG-3 antibody relatlimab, with Opdivo in the fixed-dose combo Opdualag and a $27,389-per-dose price, is the first approved in a new class of checkpoint inhibitors since the anti-PD-1/PD-L1s.
You may also be interested in...
Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy
The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.
Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond
Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution.
Fewer Drug Launches In 2022, But Standouts Among Them
Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.